Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Current Report on Form 8-K on June 5, 2025. The filing pertains to a specific corporate event regarding the company's clinical development pipeline rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory disclosure event and does not contain financial statements or performance metrics.
Material Changes
There are no material financial changes reported in this document. The primary event is the announcement that the company's broad-spectrum protease inhibitor, CDI-988, will be featured in an oral presentation at the 2025 Military Health System Research Symposium.
Guidance, Outlook, and Risks
Management commentary is limited to the press release furnished as Exhibit 99.1, which highlights the upcoming scientific presentation. The filing explicitly states that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings. No specific financial guidance, risks, or contingencies are detailed in the text of this 8-K.
Investor Verification Checklist
- Verify the content of the press release (Exhibit 99.1) regarding the CDI-988 presentation at the 2025 Military Health System Research Symposium.
- Confirm the trading status of Common Stock (COCP) on The Nasdaq Capital Market.
- Review subsequent filings for any financial impact or updated clinical data resulting from the symposium presentation.